Literature DB >> 18724359

Identification of ALK as a major familial neuroblastoma predisposition gene.

Yaël P Mossé1, Marci Laudenslager, Luca Longo, Kristina A Cole, Andrew Wood, Edward F Attiyeh, Michael J Laquaglia, Rachel Sennett, Jill E Lynch, Patrizia Perri, Geneviève Laureys, Frank Speleman, Cecilia Kim, Cuiping Hou, Hakon Hakonarson, Ali Torkamani, Nicholas J Schork, Garrett M Brodeur, Gian P Tonini, Eric Rappaport, Marcella Devoto, John M Maris.   

Abstract

Neuroblastoma is a childhood cancer that can be inherited, but the genetic aetiology is largely unknown. Here we show that germline mutations in the anaplastic lymphoma kinase (ALK) gene explain most hereditary neuroblastomas, and that activating mutations can also be somatically acquired. We first identified a significant linkage signal at chromosome bands 2p23-24 using a whole-genome scan in neuroblastoma pedigrees. Resequencing of regional candidate genes identified three separate germline missense mutations in the tyrosine kinase domain of ALK that segregated with the disease in eight separate families. Resequencing in 194 high-risk neuroblastoma samples showed somatically acquired mutations in the tyrosine kinase domain in 12.4% of samples. Nine of the ten mutations map to critical regions of the kinase domain and were predicted, with high probability, to be oncogenic drivers. Mutations resulted in constitutive phosphorylation, and targeted knockdown of ALK messenger RNA resulted in profound inhibition of growth in all cell lines harbouring mutant or amplified ALK, as well as in two out of six wild-type cell lines for ALK. Our results demonstrate that heritable mutations of ALK are the main cause of familial neuroblastoma, and that germline or acquired activation of this cell-surface kinase is a tractable therapeutic target for this lethal paediatric malignancy.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18724359      PMCID: PMC2672043          DOI: 10.1038/nature07261

Source DB:  PubMed          Journal:  Nature        ISSN: 0028-0836            Impact factor:   49.962


  48 in total

1.  Activating mutations for the met tyrosine kinase receptor in human cancer.

Authors:  M Jeffers; L Schmidt; N Nakaigawa; C P Webb; G Weirich; T Kishida; B Zbar; G F Vande Woude
Journal:  Proc Natl Acad Sci U S A       Date:  1997-10-14       Impact factor: 11.205

2.  Targeted expression of MYCN causes neuroblastoma in transgenic mice.

Authors:  W A Weiss; K Aldape; G Mohapatra; B G Feuerstein; J M Bishop
Journal:  EMBO J       Date:  1997-06-02       Impact factor: 11.598

3.  Recurrent involvement of 2p23 in inflammatory myofibroblastic tumors.

Authors:  C A Griffin; A L Hawkins; C Dvorak; C Henkle; T Ellingham; E J Perlman
Journal:  Cancer Res       Date:  1999-06-15       Impact factor: 12.701

4.  Molecular characterization of ALK, a receptor tyrosine kinase expressed specifically in the nervous system.

Authors:  T Iwahara; J Fujimoto; D Wen; R Cupples; N Bucay; T Arakawa; S Mori; B Ratzkin; T Yamamoto
Journal:  Oncogene       Date:  1997-01-30       Impact factor: 9.867

5.  Molecular genetic analysis of familial neuroblastoma.

Authors:  J M Maris; S M Kyemba; T R Rebbeck; P S White; E P Sulman; S J Jensen; C Allen; J A Biegel; G M Brodeur
Journal:  Eur J Cancer       Date:  1997-10       Impact factor: 9.162

6.  The Phox2B homeobox gene is mutated in sporadic neuroblastomas.

Authors:  Vera van Limpt; Alexander Schramm; Arjan van Lakeman; Peter Sluis; Alvin Chan; Max van Noesel; Frank Baas; Huib Caron; Angelika Eggert; Rogier Versteeg
Journal:  Oncogene       Date:  2004-12-09       Impact factor: 9.867

7.  Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis-retinoic acid. Children's Cancer Group.

Authors:  K K Matthay; J G Villablanca; R C Seeger; D O Stram; R E Harris; N K Ramsay; P Swift; H Shimada; C T Black; G M Brodeur; R B Gerbing; C P Reynolds
Journal:  N Engl J Med       Date:  1999-10-14       Impact factor: 91.245

8.  Mutation and cancer: neuroblastoma and pheochromocytoma.

Authors:  A G Knudson; L C Strong
Journal:  Am J Hum Genet       Date:  1972-09       Impact factor: 11.025

9.  Chromosome localization in normal human cells and neuroblastomas of a gene related to c-myc.

Authors:  M Schwab; H E Varmus; J M Bishop; K H Grzeschik; S L Naylor; A Y Sakaguchi; G Brodeur; J Trent
Journal:  Nature       Date:  1984 Mar 15-21       Impact factor: 49.962

10.  Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin's lymphoma.

Authors:  S W Morris; M N Kirstein; M B Valentine; K G Dittmer; D N Shapiro; D L Saltman; A T Look
Journal:  Science       Date:  1994-03-04       Impact factor: 47.728

View more
  475 in total

1.  Oncogene mutation profiling of pediatric solid tumors reveals significant subsets of embryonal rhabdomyosarcoma and neuroblastoma with mutated genes in growth signaling pathways.

Authors:  Neerav Shukla; Nabahet Ameur; Ismail Yilmaz; Khedoudja Nafa; Chyau-Yueh Lau; Angela Marchetti; Laetitia Borsu; Frederic G Barr; Marc Ladanyi
Journal:  Clin Cancer Res       Date:  2011-12-05       Impact factor: 12.531

2.  ALK germline mutations in patients with neuroblastoma: a rare and weakly penetrant syndrome.

Authors:  Franck Bourdeaut; Sandrine Ferrand; Laurence Brugières; Marjorie Hilbert; Agnès Ribeiro; Ludovic Lacroix; Jean Bénard; Valérie Combaret; Jean Michon; Dominique Valteau-Couanet; Bertrand Isidor; Xavier Rialland; Maryline Poirée; Anne-Sophie Defachelles; Michel Peuchmaur; Gudrun Schleiermacher; Gaëlle Pierron; Marion Gauthier-Villars; Isabelle Janoueix-Lerosey; Olivier Delattre
Journal:  Eur J Hum Genet       Date:  2011-11-09       Impact factor: 4.246

3.  Differential inhibitor sensitivity of anaplastic lymphoma kinase variants found in neuroblastoma.

Authors:  Scott C Bresler; Andrew C Wood; Elizabeth A Haglund; Joshua Courtright; Lili T Belcastro; Jefferson S Plegaria; Kristina Cole; Yana Toporovskaya; Huaqing Zhao; Erica L Carpenter; James G Christensen; John M Maris; Mark A Lemmon; Yaël P Mossé
Journal:  Sci Transl Med       Date:  2011-11-09       Impact factor: 17.956

4.  Antibody targeting of anaplastic lymphoma kinase induces cytotoxicity of human neuroblastoma.

Authors:  E L Carpenter; E A Haglund; E M Mace; D Deng; D Martinez; A C Wood; A K Chow; D A Weiser; L T Belcastro; C Winter; S C Bresler; M Vigny; P Mazot; S Asgharzadeh; R C Seeger; H Zhao; R Guo; J G Christensen; J S Orange; B R Pawel; M A Lemmon; Y P Mossé
Journal:  Oncogene       Date:  2012-01-23       Impact factor: 9.867

Review 5.  New aspects of neuroblastoma treatment: ASPHO 2011 symposium review.

Authors:  Peter E Zage; Chrystal U Louis; Susan L Cohn
Journal:  Pediatr Blood Cancer       Date:  2012-02-29       Impact factor: 3.167

Review 6.  Emerging importance of ALK in neuroblastoma.

Authors:  Anna M Azarova; Gargi Gautam; Rani E George
Journal:  Semin Cancer Biol       Date:  2011-09-16       Impact factor: 15.707

7.  ALK mutations conferring differential resistance to structurally diverse ALK inhibitors.

Authors:  Johannes M Heuckmann; Michael Hölzel; Martin L Sos; Stefanie Heynck; Hyatt Balke-Want; Mirjam Koker; Martin Peifer; Jonathan Weiss; Christine M Lovly; Christian Grütter; Daniel Rauh; William Pao; Roman K Thomas
Journal:  Clin Cancer Res       Date:  2011-09-26       Impact factor: 12.531

8.  Nervous system: Embryonal tumors: Neuroblastoma.

Authors:  Caileigh Pudela; Skye Balyasny; Mark A Applebaum
Journal:  Atlas Genet Cytogenet Oncol Haematol       Date:  2020-07

9.  Telomere Maintenance Mechanisms Define Clinical Outcome in High-Risk Neuroblastoma.

Authors:  Balakrishna Koneru; Gonzalo Lopez; Ahsan Farooqi; Karina L Conkrite; Thinh H Nguyen; Shawn J Macha; Apexa Modi; Jo Lynne Rokita; Eduardo Urias; Ashly Hindle; Heather Davidson; Kristyn Mccoy; Jonas Nance; Vanda Yazdani; Meredith S Irwin; Shengping Yang; David A Wheeler; John M Maris; Sharon J Diskin; C Patrick Reynolds
Journal:  Cancer Res       Date:  2020-04-14       Impact factor: 12.701

Review 10.  New insights into the genetics of neuroblastoma.

Authors:  Srishma Sridhar; Batool Al-Moallem; Hawra Kamal; Marta Terrile; Raymond L Stallings
Journal:  Mol Diagn Ther       Date:  2013-04       Impact factor: 4.074

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.